Genenta Science, a pioneer in immuno-oncology, and Anemocyte, a leading provider of advanced therapy and nucleic acid solutions, have announced an expanded strategic collaboration focused on developing an off-the-shelf lentiviral vector (LVV) Plasmid DNA technology platform.

The new agreement builds on their successful existing partnership centred on plasmid DNA production. By combining Genenta’s clinically validated LVV Plasmid DNA technology—originally developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta—with Anemocyte’s advanced manufacturing capabilities, the partnership aims to deliver a reliable and scalable source of high-quality materials for the life sciences sector.

The collaboration will allow Anemocyte to strengthen its offering to clients across the therapeutic development spectrum, providing consistent quality materials from research and development through to GMP grade, and from preclinical to commercial stages.

“Our expanded collaboration with Anemocyte represents a natural evolution of our successful partnership in plasmid DNA manufacturing,” said Pierluigi Paracchi, CEO of Genenta Science. “By making our LVV Plasmid DNA platform available to Anemocyte and its clients, we are enabling reliable and scalable development of advanced therapy programmes across the industry.”

Marco Ferrari, CEO of Anemocyte, added, “Our collaboration with Genenta has already delivered excellent results. By formalising this new partnership, we are ensuring our clients gain access to a proven, robust platform for their advanced therapy initiatives, supported by Genenta’s extensive expertise.”

The collaboration marks an important milestone for both companies, reinforcing their shared commitment to driving innovation and reliability in life sciences and advanced therapies.

Anemocyte, a biotech manufacturing organisation (BMO) based in Italy, provides integrated development and manufacturing solutions, offering expertise in pDNA and mRNA production and over 25 years of experience in advanced therapy development.

Genenta Science is a clinical-stage immuno-oncology company developing proprietary haematopoietic stem cell gene therapies for the treatment of various solid tumours.